AgomAb Therapeutics NV (AGMB) Income Statement
AGMB 2025 at a glance
Fiscal year ended December 31, 2025 · eurosAGMB revenue and net income
AGMB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AGMB income statement in euros
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| Cost of revenue | €210,356 | — | — | — |
| Gross profit | −€210,356 | — | — | — |
| Research & development | €48.9M | €39.3M | €26.3M | €19.4M |
| Sales, general & admin | €12.6M | €9.8M | €6.0M | €4.5M |
| Total operating expenses | €59.3M | €48.0M | €31.2M | €22.6M |
| Operating income | −€59.3M | −€48.0M | −€31.2M | −€22.6M |
| Interest income | €1.6M | €1.2M | €245,000 | €71,000 |
| Interest expense | €60,000 | €67,000 | €31,000 | €45,000 |
| Income before taxes | −€62.5M | −€46.3M | −€12.0M | −€10.8M |
| Income taxes | €4,000 | €4,000 | −€619,000 | −€2.7M |
| Net income | −€62.5M | −€46.3M | −€11.4M | −€8.1M |
| EBITDA | −€62.3M | −€45.9M | −€11.9M | −€10.7M |
| Mar '26 | Dec '25 | Sep '25 | Dec '24 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| Research & development | €10.7M | €13.9M | €13.0M | €10.7M |
| Sales, general & admin | €1.4M | €3.3M | €2.6M | €1.4M |
| Total operating expenses | €11.8M | €16.5M | €15.4M | €11.8M |
| Operating income | −€11.8M | −€16.5M | −€15.4M | −€11.8M |
| Interest income | — | €581,000 | €173,000 | €471,000 |
| Interest expense | — | €139,000 | €124,000 | €155,000 |
| Income before taxes | −€11.7M | −€17.4M | −€18.3M | −€11.7M |
| Income taxes | €4,000 | — | — | €4,000 |
| Net income | −€11.7M | −€17.4M | −€18.3M | −€11.7M |
| EBITDA | −€11.8M | −€17.6M | −€18.0M | −€11.8M |
Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported in AGMB's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AGMB financial results
AgomAb Therapeutics NV reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of €62.5 million. Figures are in euros, the currency of its financial statements.
See the AGMB stock overview for the latest quote and news, or the AGMB chart for price history and technical indicators.
AGMB income statement FAQ
Does AgomAb Therapeutics NV have revenue?
AgomAb Therapeutics NV reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is AgomAb Therapeutics NV profitable?
No. AgomAb Therapeutics NV reported a net loss of €62.5 million in fiscal 2025.
How much does AgomAb Therapeutics NV spend on research and development?
AgomAb Therapeutics NV spent €48.9 million on research and development in fiscal 2025.
When does AgomAb Therapeutics NV's fiscal year end?
AgomAb Therapeutics NV's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.